ELXMF Stock Chart & Stats
$0.01
$0.01(652.89%)
At close: 4:00 PM EDT
$0.01
$0.01(652.89%)
Day’s Range― - ―
52-Week Range$0.01 - $0.25
Previous CloseN/A
Volume5.00K
Average Volume (3M)0.00
Market Cap
$26.04M
Enterprise Value$35.08M
Total Cash (Recent Filing)$2.62M
Total Debt (Recent Filing)$4.94M
Price to Earnings (P/E)―
Beta6.17
Next Earnings
Aug 26, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.03
Shares Outstanding284,875,270
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio0.20
Price to Book (P/B)1.43
Price to Sales (P/S)0.93
P/FCF Ratio-4.14
Enterprise Value/Market Cap1.35
Enterprise Value/Revenue1.06
Enterprise Value/Gross Profit1.59
Enterprise Value/Ebitda-8.99
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)>-0.01
Revenue Forecast (FY)$29.80M
Bulls Say, Bears Say
Bulls Say
Revenue GrowthA 12.09% year-over-year revenue increase shows the company is expanding sales and market traction. Over a 2–6 month horizon, persistent top-line growth supports scaling of fixed-cost-intensive medical device operations and provides a pathway to leverage revenue into improved margins if cost trends are managed.
Low LeverageA low debt-to-equity ratio (0.16) implies limited financial leverage and lower refinancing risk. This structural strength gives management flexibility to fund regulatory work, commercial rollout or R&D via equity or modest debt without excessive interest burden, supporting durability through loss-making periods.
Improving EPS TrendReported EPS growth of ~33% indicates an improving earnings trajectory versus prior periods. If this trend reflects operational improvements rather than one-offs, it signals narrowing losses and progressing unit economics, which is a durable precursor to eventual sustained profitability for a device maker.
Bears Say
Negative Cash GenerationConsistent negative operating and free cash flows indicate the business is burning cash to run and grow operations. For a medical device firm, prolonged negative cash generation raises funding reliance, dilution risk or the need for debt, constraining long-term R&D, commercialization and competitiveness unless cash generation reverses.
Gross Margin CompressionA sharp gross margin decline from 86.6% to 68.6% suggests rising unit costs, adverse product mix, or pricing pressure. Margin compression reduces the buffer to absorb SG&A and R&D, making achieving sustainable profitability more difficult and requiring structural cost or pricing responses to restore long-term margin durability.
Ongoing Losses & Negative ROEPersistent negative net and EBIT margins, alongside negative ROE, show the company is not yet delivering returns on shareholder capital. This fundamental weakness undermines reinvestment capacity and investor support unless management can demonstrate durable operational improvements toward sustained profitability.
Nova Eye Medical News
ELXMF FAQ
What was Nova Eye Medical’s price range in the past 12 months?
Nova Eye Medical lowest stock price was $0.01 and its highest was $0.25 in the past 12 months.
What is Nova Eye Medical’s market cap?
Nova Eye Medical’s market cap is $26.04M.
When is Nova Eye Medical’s upcoming earnings report date?
Nova Eye Medical’s upcoming earnings report date is Aug 26, 2026 which is in 21 days.
How were Nova Eye Medical’s earnings last quarter?
Nova Eye Medical released its earnings results on Feb 25, 2026. The company reported -$0.008 earnings per share for the quarter, missing the consensus estimate of -$0.004 by -$0.005.
Is Nova Eye Medical overvalued?
According to Wall Street analysts Nova Eye Medical’s price is currently Overvalued.
Does Nova Eye Medical pay dividends?
Nova Eye Medical pays a Notavailable dividend of $0.294 which represents an annual dividend yield of N/A. See more information on Nova Eye Medical dividends here
What is Nova Eye Medical’s EPS estimate?
Nova Eye Medical’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Nova Eye Medical have?
Nova Eye Medical has 284,875,270 shares outstanding.
What happened to Nova Eye Medical’s price movement after its last earnings report?
Nova Eye Medical reported an EPS of -$0.008 in its last earnings report, missing expectations of -$0.004. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Nova Eye Medical?
Currently, no hedge funds are holding shares in ELXMF
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Nova Eye Medical Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Blogger Sentiment
Bullish
ELXMF Sentiment 100%
Sector Average 64%
Sector Average 64%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-0.64%
Trailing 12-Months
Company Description
Nova Eye Medical
Nova Eye Medical Limited specializes in the creation, advancement, distribution, marketing, sale, and servicing of surgical equipment dedicated to treating glaucoma. Its diverse product line features iTrack, a surgical system engineered to decrease intraocular pressure (IOP) in adult patients with open-angle glaucoma, and iTrack Advance, an innovative system promoting natural ocular fluid drainage. Furthermore, the company provides Molteno3, a glaucoma drainage device for individuals suffering from severe or intricate forms of the condition, alongside 2RT, a proprietary laser technology employed to address early to intermediate stages of age-related macular degeneration. With a presence spanning Australia, the United States, Europe, the Asia Pacific, and other international markets, the company, originally established in 1985 as Ellex Medical Lasers Limited, officially became Nova Eye Medical Limited in July 2020. Its corporate headquarters are situated in Kent Town, Australia.
Technical Analysis
Cochlear
―
Compumedics Limited
―
Somnomed Limited
―
EMvision Medical Devices Ltd.
―
Control Bionics Ltd.
―